Randomized Trialvery high evidence
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The New England journal of medicine·July 11, 2024·PMID 38785209
Why it mattersThis is the first dedicated renal outcomes trial showing that a GLP-1 receptor agonist reduces clinically important kidney events in patients with type 2 diabetes and CKD, addressing a major evidence gap.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled